EADV 2025: Interim Real-World Data from ADlife on Lebrikizumab in Moderate-to-Severe AD
New interim real-world data from the ADlife study explore the effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis. Early results at weeks 4 and 16 suggest promising clinical outcomes in a comorbid, treatment-experienced population.
Image courtesy of the European Academy of Dermatology and Venereology (EADV).
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
